All In Biotech

Investigational drug · Phase 2

JNJ-90014496

Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse.

Phase 2

Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

1

1 still active

All registered trials

1

Any phase or sponsor naming "JNJ-90014496"

First trial start

2022

Aug 12, 2022

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "JNJ-90014496", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Lymphoma, Non-Hodgkin
  • Lymphoma, B-Cell
  • Lymphoma, Large B-Cell, Diffuse

Approved drugs for the same conditions: Lymphoma (non-Hodgkin) · Hematology and blood cancers

Largest trials

Live from ClinicalTrials.gov: studies naming "JNJ-90014496" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 0 on PubMed

No PubMed records name it yet, which is common for early code-named drugs.

Also in development for Lymphoma, Non-Hodgkin

  • CC-99282BMS-986369, GolcadomidePhase 37 trials

    Bristol Myers Squibb · Lymphoma, Follicular, Large B-cell Lymphoma, Non-Hodgkin Lymphoma

  • MK-1045CN-201Phase 36 trials

    Merck & Co. · Lymphoma, Large B-Cell, Diffuse, Lymphoma, Non-Hodgkin, Lymphoma, Follicular

  • RimiducidAP1903Phase 23 trials

    Bellicum Pharmaceuticals · Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, Leukemia, Acute Myeloid (AML), Child

  • valemetostat tosylateDS-3201bPhase 23 trials

    Daiichi Sankyo · Non-small Cell Lung Cancer, Lung Cancer, Relapsed/Refractory Peripheral T-Cell Lymphoma

  • rivogenlecleucelBPX-501 T cells, BPX-501Phase 22 trials

    Bellicum Pharmaceuticals · Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, Leukemia, Acute Myeloid (AML), Child

  • GSK5926371Phase 21 trial

    GSK · Lymphoma, Non-Hodgkin

  • JMBI-001Phase 21 trial

    Chengdu Anticancer Bioscience, Ltd. · Advance Solid Tumors, Lymphoma, Non-Hodgkin

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Johnson & Johnson (Janssen).

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.